A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2018-03-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of two fixed doses of vortioxetine (Lu
AA21004; 10 or 20 mg/day) after 8 weeks of treatment in patients with major depressive
disorder (MDD) in Japan.